We want to share our knowledge with the Life Sciences industry in the hope that this information may help you overcome the challenges you face across all stages of the drug development process.
After intense research investigations Heidelberg Pharma found a unique access to a fully synthetic route for α-Amanitin. With CARBOGEN AMCIS, Heidelberg Pharma developed a scalable and economical route providing α-Amanitin now available for the development of new therapeutic ADC’s.
A joint effort of CARBOGEN AMCIS and Takeda Pharmaceutical - Dr. G Elena Daia (Process R&D Team Leader) at CARBOGEN AMCIS Ltd.
Wednesday, 17 June 2020
The following case study is one example of how CARBOGEN AMCIS helps customers to advance their projects with a dedicated team and state-of-the-art techniques.